News | March 09, 2021
Vivimed Labs receives products approvals from Uzbekistan
Vivimed strategy is to increase its share of Branded products in CIS Markets.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
Healthcare and consumer wellness leader brings extensive experience in business transformation, commercial strategy and growth leadership to Fertin India
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Funds to support product expansion, quick commerce growth, and manufacturing scale-up for holistic period care solutions
Early implementation of West Synchrony S1 platform aims to accelerate biologics and vaccine development while reducing manufacturing risk for biopharma partners
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
Subscribe To Our Newsletter & Stay Updated
